PAVmed Inc. Q4 FY2025 earnings call

• Framed PABMED's current position after completing restructuring, recapitalization, and financing to fix legacy capital structure. - Discussed Lucid's operational highlights including eCigar revenue growth, VA contract, and positive esophageal precancer detection data. - Talked about VERUS's commercial engagement with OSU, progress with implantable physiologic monitor, and expanded strategic vision. - Mentioned relaunching MedTech portfolio with new chief business officer, work on Port.io, technology from Duke, and evaluating inbound inquiries for medical technologies

Lucid: Fourth quarter 2025 eCigar revenue was approximately $1.5 million at eCigar test volume of 3,664 eCigar tests, volume increased 29% from third quarter and revenue increased 24% over third quarter; Lucid was awarded a U.S. Department of Veterans Affairs contract for ESAGARD and announced positive data for the largest real-world experience of esophageal precancer detection. Verus: Commercial phase of engagement with Ohio State University is well underway, completed full EPIC integration with OSU with positive feedback; making solid progress with implantable physiologic monitor, expect late submission to FDA under 510 designation later this year; developing expanded strategic vision to move from pure play remote patient monitoring to AI and AI-based tools, clinical decision tools. MedTech portfolio: Engaged new chief business officer, working on relaunching, including Port.io and technology licensed from Duke, evaluating inbound inquiries for medical technologies

Q: Focus on commercial relationship with OSU, key metrics and timeframe for rolling out to other institutions; A: Target of a thousand patients within first year, on track with EHR integration, focusing capital resources on implantable device FDA submission and clearance, clinical support side important for broader expansion.

Q: Risk stratification tools and integration with OSU platform; A: AI-based tools in early stages, partnership with OSU on development, evolving from remote patient monitoring to AI-based clinical decision support tools.

Q: New imaging technology licensed from Duke, clinical work and commercial plans; A: Technology in early phases, optical technology combines OSC and ALCI, work on modifying probe, redesign underway, once design freeze, secure 510 FDA pathway for clearance and commercialization.

Q: Particular areas or products interested in for medical device portfolio; A: Got inquiries across diagnostic, electrodiagnostic, medical devices, pharma assets, open for inquiries across board, interested in GI space related technologies